Search results
Showing 16 to 30 of 281 results for covid-19
NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Awaiting development Reference number: GID-TA11224 Expected publication date: TBC
Awaiting development Reference number: GID-TA11226 Expected publication date: TBC
Awaiting development Reference number: GID-TA11227 Expected publication date: TBC
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.
School-based interventions: physical and mental health and wellbeing promotion
In development Reference number: GID-QS10070 Expected publication date: TBC
risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk...
Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have...